TNFRSF17 and Miyoshi myopathy: Thus, the combination of belantamab mafodotin and γ-secretase inhibitor (GSI) could have a synergistic effect, avoiding the resistance to belantamab mafodotin for the loss of BCMA on the surface of MM cells, and it is being investigated in the DREAMM-5 clinical trial (NCT04126200) [156].